Cordis releases cobalt chromium Palmaz Blue biliary stent in the US:
This article was originally published in Clinica
Cordis has launched in the US its balloon-expandable Palmaz Blue transhepatic biliary cobalt chromium stent for opening blocked bile ducts. Featuring L605, a cobalt alloy enhanced with tungsten, the device is stronger than stainless steel stents and uses less metal, claims the company. As well as being stronger, the stent has a low profile and offers improvements in radiopacity, flexibility and deliverability, the firm added. Cordis, a Johnson & Johnson company, said that each year in the US, over 30,000 people are affected by life-threatening bile duct blockages.f
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.